Onco-hematology Molecular Testing Market Size, Share & Trends Analysis Report By Blood Cancer Type, By Technology, By Blood Cancer Biomarker, By End-User, By Region, And By Segment Forecasts, 2023-2031

Report Id: 1995 Pages: 180 Last Updated: 16 October 2024 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Onco-hematology Molecular Testing Market-

Onco-hematology Molecular Testing Market

  • Onco-hematology Molecular Testing Market By Blood Cancer Type
    • Chronic Myeloid Leukemia
      • Polycythemia Vera
      • Essential Thrombocythaemia
      • Myelofibrosis
    • Myeloproliferative Neoplasms
    • Acute Myeloid Leukemia
    • Acute Lymphoblastic Leukemia
  • Onco-hematology Molecular Testing Market By Technology
    • qPCR
    • dPCR
    • Next-Generation Sequencing
    • Others
  • Onco-hematology Molecular Testing Market By Blood Cancer Biomarker
    • BCR-ABL1 Mbcr
    • JAK2
    • CALR
    • MPL
    • PML-RARA
    • NPM1
    • RUNX1-RUNX1T1
    • CBFB-MYH11
    • BCR-ABL1 mbcr
  • Onco-hematology Molecular Testing Market By End-user
    • National Reference Lab / Specialty Lab
    • University Hospital / Oncology Center
    • Community Hospital / IDN (Regional/National)

Onco-hematology Molecular Testing Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Onco-hematology Molecular Testing Market Snapshot

Chapter 4. Global Onco-hematology Molecular Testing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Metaverse Industry
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. COVID-19 Impact on Metaverse Industry

Chapter 5. Market Segmentation 1: By Blood Cancer Type Estimates & Trend Analysis
5.1. By Blood Cancer Type & Market Share, 2019-2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Blood Cancer Type:

5.2.1. Chronic Myeloid Leukemia

5.2.1.1. Polycythemia Vera
5.2.1.2. Essential Thrombocythemia
5.2.1.3. Myelofibrosis

5.2.2. Myeloproliferative Neoplasms
5.2.3. Acute Myeloid Leukemia
5.2.4. Acute Lymphoblastic Leukemia

Chapter 6. Market Segmentation 2: By Technology Estimates & Trend Analysis
6.1. By Blood Cancer Type & Market Share, 2019-2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Technology:

6.2.1. qPCR
6.2.2. dPCR
6.2.3. Next-Generation Sequencing
6.2.4. Others

Chapter 7. Market Segmentation 3: By Blood Cancer Biomarker Estimates & Trend Analysis
7.1. By Blood Cancer Type & Market Share, 2019-2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Blood Cancer Biomarker:

7.2.1. BCR-ABL1 Mbcr
7.2.2. JAK2
7.2.3. CALR
7.2.4. MPL
7.2.5. PML-RARA
7.2.6. NPM1
7.2.7. RUNX1-RUNX1T1
7.2.8. CBFB-MYH11
7.2.9. BCR-ABL1 mbcr

Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. By Blood Cancer Type & Market Share, 2019-2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By End User:

8.2.1. National Reference Lab / Specialty Lab
8.2.2. University Hospital / Oncology Center
8.2.3. Community Hospital / IDN (Regional/National)

Chapter 9. Onco-hematology Molecular Testing Market Segmentation 5: Regional Estimates & Trend Analysis

9.1. North America

9.1.1. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Type, 2023-2031
9.1.2. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.1.3. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker, 2023-2031
9.1.4. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By, End User 2023-2031
9.1.5. North America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts by country, 2023-2031

9.1.5.1. U.S.
9.1.5.2. Canada

9.2. Europe

9.2.1. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) by By Blood Cancer Type, 2023-2031
9.2.2. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.2.3. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker 2023-2031
9.2.4. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By End User,2023-2031
9.2.5. Europe Onco-hematology Molecular Testing Market revenue (US$ Million) by country, 2023-2031

9.2.5.1. Germany
9.2.5.2. Poland
9.2.5.3. France
9.2.5.4. Italy
9.2.5.5. Spain
9.2.5.6. UK
9.2.5.7. Rest of Europe

9.3. Asia Pacific

9.3.1. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) by By Blood Cancer Type, 2023-2031
9.3.2. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.3.3. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker, 2023-2031
9.3.4. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By End User, 2023-20
9.3.5. Asia Pacific Onco-hematology Molecular Testing Market revenue (US$ Million) by country, 2023-2031

9.3.5.1. China
9.3.5.2. India
9.3.5.3. Japan
9.3.5.4. Australia
9.3.5.5. Rest of Asia Pacific

9.4. Latin America

9.4.1. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) by By Blood Cancer Type, 2023-2031
9.4.2. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.4.3. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker, 2023-2031
9.4.4. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By End User, 2023-2031
9.4.5. Latin America Onco-hematology Molecular Testing Market revenue (US$ Million) by country, (US$ Million) 2023-2031

9.4.5.1. Brazil
9.4.5.2. Rest of Latin America

9.5. Middle East & Africa

9.5.1. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) by By Blood Cancer Type, (US$ Million)
9.5.2. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Technology, 2023-2031
9.5.3. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By Blood Cancer Biomarker, 2023-2031
9.5.4. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) estimates and forecasts By End User, 2023-2031
9.5.5. Middle East & Africa Onco-hematology Molecular Testing Market revenue (US$ Million) by country, (US$ Million) 2023-2031

9.5.5.1. South Africa
9.5.5.2. GCC Countries
9.5.5.3. Rest of MEA

Chapter 10. Competitive Landscape

10.1. Major Mergers and Acquisitions/Strategic Alliances

10.2. Company Profiles

10.2.1. Asusragen, Inc.
10.2.2. Bio-Rad Laboratories, Inc.
10.2.3. ICON plc
10.2.4. Illumina, Inc.
10.2.5. Integrated DNA Technologies, Inc. (ArcherDx, Inc.)
10.2.6. Invivoscribe, Inc.
10.2.7. QIAGEN N.V.
10.2.8. Thermo Fisher Scientific, Inc.
10.2.9. Cepheid

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
5426
Security Code field cannot be blank!

Frequently Asked Questions

The Onco-hematology Molecular Testing Market Size is valued at USD 497.67 Mn in 2022 and is predicted to reach USD 1280.06 Mn by the year 2031

Onco-hematology Molecular Testing Market expected to grow at a 11.2 % CAGR during the forecast period for 2023-2031

Asuragen, Inc., Bio-Rad Laboratories, Inc., ICON plc, Illumina, Inc., Integrated DNA Technologies, Inc. (ArcherDx, Inc.), Invivoscribe, Inc., QIAGEN N

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying